Insilico Medicine and TaiGen Biotechnology have unveiled an exclusive out-licensing partnership concerning a specific pipeline. Under this agreement, Insilico Medicine confers upon TaiGen the exclusive rights to develop, market, and sublicense ISM4808—an AI-driven, potentially "best-in-class" oral PHD inhibitor—within the Greater China region. In 2023, this drug secured clinical trial approval for treating anemia associated with chronic kidney disease (CKD). TaiGen is set to acquire the pertinent development and commercialization rights. Meanwhile, Insilico Medicine stands to gain an initial payment, milestone-based payments, and tiered royalties, with the overall deal value soaring into the tens of millions of US dollars.

ISM4808, which was nominated in 2022, specifically targets the HIF-α pathway. Its innovative structure was crafted using Insilico Medicine's proprietary engine. Preclinical investigations have underscored the drug's robust efficacy and exceptional oral bioavailability. Both Dr. Ren Feng, the Co-CEO of Insilico Medicine, and Huang Guolong, the Chairman of TaiGen Biotechnology, have voiced their enthusiasm and high expectations for this collaborative endeavor.